Veracyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Veracyte and other ETFs, options, and stocks.

About VCYT

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. 

CEO
Marc A. Stapley
CEOMarc A. Stapley
Employees
755
Employees755
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2006
Founded2006
Employees
755
Employees755

VCYT Key Statistics

Market cap
3.78B
Market cap3.78B
Price-Earnings ratio
43.57
Price-Earnings ratio43.57
Dividend yield
Dividend yield
Average volume
1.31M
Average volume1.31M
High today
High today
Low today
Low today
Open price
$47.51
Open price$47.51
Volume
0.00
Volume0.00
52 Week high
$50.71
52 Week high$50.71
52 Week low
$22.61
52 Week low$22.61

Stock Snapshot

Veracyte(VCYT) stock is priced at $47.33, giving the company a market capitalization of 3.78B. It carries a P/E multiple of 43.57.

During the trading day, Veracyte(VCYT) stock saw an opening price of $47.51, a peak of —, and a bottom of —.

Trading volume for Veracyte(VCYT) stock has reached 0, versus its average volume of 1.31M.

Over the past 52 weeks, Veracyte(VCYT) stock has traded between a high of $50.71 and a low of $22.61.

Over the past 52 weeks, Veracyte(VCYT) stock has traded between a high of $50.71 and a low of $22.61.

VCYT News

TipRanks 4d
Veracyte shareholders endorse board, pay and incentive plans

Veracyte ( (VCYT) ) has provided an update. At its recent annual meeting, Veracyte stockholders elected nine directors, including Eliav Barr, Muna Bhanji, Kari...

Simply Wall St 6d
Assessing Veracyte Valuation After New Prosigna Launch And Decipher Prostate Clinical Milestones

Veracyte (VCYT) is in focus after a busy period of clinical milestones, led by the U.S. commercial launch of its Prosigna Breast Risk of Recurrence test and new...

Assessing Veracyte Valuation After New Prosigna Launch And Decipher Prostate Clinical Milestones

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
9.1%
Sell
9.1%

People also own

Based on the portfolios of people who own VCYT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.